A
A
Home

The Latest

News

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis

Breda, the Netherlands – August 25, 2021
argenx today announced that it has submitted, and the European Medicines Agency (EMA) has validated, the marketing authorization application (MAA) for the Company’s investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.
Read
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis

More Press Releases

Show more Press Releases

Media center

April 7, 2020
SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics
April 7, 2020
SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
April 7, 2020
SIMPLE Antibody platform / DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops
April 7, 2020
Cusatuzumab / International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
April 7, 2020
Cusatuzumab / ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade